Harrow has handed the licensing rights to Apotex for five of its ophthalmic assets in Canada that are in different phases of commercialization and development.
The Canadian company Apotex has snapped up rights to five ophthalmic products from eyecare pharma player Harrow as part of an exclusive out-licensing agreement that will grant the Canadian player commercialization and development rights to assets at different stages of development in its country.
As such, Apotex will market and distribute the drug Verkazia (cyclosporine ophthalmic 0.1% emulsion) alongside an over-the-counter product Cationorm Plus...
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.
